These results are consistent with the phenotype of hyperprolactinemia patients, who experience bone loss [100], thought to be either due to the indirect effect of PRL that results in hypogonadism, and therefore, low estrogen, or alternatively by the direct action of PRL on osteoblasts [99,101]. The gene discussed is PRL; the disease is hyperprolactinemia.